anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND AND AIMS: Both iron overload and iron deficiency have been associated with cardiovascular diseases in observational studies. Previous Mendelian Randomization (MR) studies discovered a protective effect of higher iron status on coronary atrial disease, while a neutral effect on all-cause heart failure. Using two-sample MR, we evaluated how genetically predicted systemic iron status affects the risk of non-ischemic cardiomyopathy and different phenotypes.
METHODS AND RESULTS: Two-sample MR analyses were performed to estimate the causal effect of four biomarkers of systemic iron status on diagnosed cardiomyopathy and its subtypes in 242,607 participants from the FinnGen research project. The level of transferrin saturation was significantly associated with an increased risk of cardiomyopathy (OR, 1.17; 95% CI, 1.13-1.38) when using nine separately selected genetic instruments. An increase in genetically determined serum iron (odds ratio [OR] per standard deviation [SD], 1.25; 95% confidence interval [CI], 1.13-1.38) and ferritin (OR, 1.49; 95% CI, 1.02-2.18) were associated with an increased risk of cardiomyopathy. Total iron binding capacity, a marker of reduced iron status, was inversely linked with cardiomyopathy (OR, 0.80; 95% CI, 0.65-0.98). The risk effect of iron status was more evident in hypertrophic cardiomyopathy and related heart failure.
CONCLUSIONS: These analyses support the causal effect of increased systemic iron status on a higher risk of non-ischemic cardiomyopathy. A screening test for cardiomyopathy should be considered in patients with evidence of iron overload. Future study is needed for exploring the mechanism of these causal variants on cardiomyopathy.
A decision-support system and computer implemented method automatically measures tee midline shift in a patient's brain using Computed Tomography (CT) images. The decision-support system and computer implemented method applies machine learning methods to features extracted from multiple sources, including midline shift, blood amount, texture pattern and other injury data, to provide a physician an estimate of intracranial pressure (ICP) levels. A hierarchical segmentation method, based on Gaussian Mixture Mode! (GMM), is used. In this approach, first an Magnetic Resonance Image (MRI) ventricle template, as prior knowledge, is used to estimate the region for each ventricle. Then, by matching the ventricle shape it) CT images to fee MRI ventricle template set, the corresponding MRI slice is selected. From the shape matching result, the feature points for midline estimation in CT slices, such as the center edge points of the lateral ventricles, are detected. The amount of shift, along with other information such as brain tissue texture features, volume of blood accumulated in the brain, patient demographics, injury information, and features extracted from physiological signals, are used to train a machine learning method to predict a variety of important clinical factors, such as intracranial pressure (ICP), likelihood of success a particular treatment, and the need and/or dosage of particular drugs.
One or more phytocannabinoids, selected from the group consisting of tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), tetrahydrocannabivarinic acid, (THCVA), tetrahydrocannabinolic acid (THCA), cannabidiolic acid (CBDA), cannabidol (CBD), cannabigerol (CBG) and cannabichromene (CBC), are provided for use in the treatment of prostate cancer. Where present the THCVA is present in an isolated pytocannabinoid, the THCA, CBDA, CBD, CBG or CBC are present in the form of a BDS, and the THCV or CBDV are present in either an isolated form or in the form of a BDS. Alternatively, one or more phytocannabinoids or acid phytocannabinoids may be provided for use in the down regulation of ERK signaling and effect one or more of anti-proliferation, anti-metastasis or anti-angiogenesis in a human patient. Alternatively, one or more phytocannabinoid acid, excluding CBDA or CBDVA, may be provided, for use in medicine. Alternatively, a cannabis plant extract for use in medicine may comprise at least 50% w/w phytocannabinoid component, the non-phytocannabinoid component comprising a monoterpene fraction and a sesquiterpene fraction. Alternatively, an isolated CBD and/or CBD BDS may be provided for use in the treatment of a pre-cancerous symptom of colon cancer. Alternatively, a combination of phytocannabinoids together with a chemotherapeutic agent may be provided for use in the treatment of a glioma.
307,011. Hauptmeyer, F., (Assignee of Krupp Akt.-Ges., F.). March 1, 1928, [Convention date]. Compositions containing metals.-A composition consisting of a powdered metal alloy neutral to chemical agents and a bond is used as a teethfilling and for objects used in the brewing industry such as vessels, piping, and apparatus. The composition is neutral to bacteria. Suitable alloys are chrome-nickel, nickel-iron, chromenickel steel and chrome-iron alloys. Suitable bonds are cements, varnishes, and water-glass preparations. In an example a tooth filling comprises finely powdered chromium-nickel-steel containing 20 per cent of chromium and 7 per cent of nickel bonded with dental cement. The Specification as open to inspection under Sect. 91 (3) (a) also comprises a method of determining the lower limit of the percentage of metal or alloy, of a mixture containing chemically neutral metal or alloy and a binder, by testing a series of trial mixes. The Specification also specifies sulphur, tar, asphalt india-rubber, resin and the like as binders, and the application of the compositions to vessels, pipes, and apparatus used in chemical industries, for stairs, floors, pavements, bricks, and solid or pneumatic tyres. This subject-matter does not appear in the Specification as accepted.
Peritoneal dialysis utilisation in Indonesia decreased yearly from 6.6% in 2014 to 1.6% in 2018. Various efforts have been made by the government and the Indonesian Nephrologist Organization (PERNEFRI) through education and regulation to optimise the use of peritoneal dialysis, but have yet to succeed. The simplicity of automated peritoneal dialysis (APD) made it worth considering as another solution to optimise peritoneal dialysis in Indonesia. Several advantages are offered by using APD, such as providing more time for activities compared to continuous ambulatory peritoneal dialysis, cheaper cost than haemodialysis and allowing remote monitoring. The advantages of APD make it a promising kidney replacement therapy (KRT) modality for developing countries like Indonesia, but the application is scarce. Some of the challenges in implementing APD in Indonesia include APD machines and fluids that are not available in the Indonesian market; the price of machines and fluids is still high; health workers are not familiar with APD; patients and their families not knowing APD as one of KRT; and APD machines distribution in archipelagic country is challenging.
In Group I, up to 100 women, at least 40 years of age, who have had a routine standard mammogram read as BI-RADS® 0, 1, 2, or 3 will also undergo 3D breast imaging using a cone beam CT scanner specifically designed to image the breast. Of these 100, we hope to enroll at least 30 subjects with mammograms read as BI-RADS® 0 and at least 30 read as BI-RADS® 3. The BI-RADS® 0 category refers to patients for whom additional imaging is required after a screening mammogram provided incomplete diagnostic information.
BACKGROUND: Atopic dermatitis ranks among the prevalent skin disorders. Research has indicated a potential association with brain cancer. Yet, establishing a direct causal relationship between atopic dermatitis and brain cancer continues to be challenging.
MATERIALS AND METHODS: We extracted single nucleotide polymorphisms (SNPs) significantly associated with atopic dermatitis (sample size = 382 254) at a genome-wide level from a large Finnish Genome-Wide Association Study (GWAS) dataset (n cases = 15 208, n controls = 367 046). Summary data for 372 622 cases of brain cancer (n cases = 606, n controls = 372 016) were obtained via the IEU Open GWAS database. We employed the Inverse Variance Weighted (IVW) method as our primary analytical approach for Mendelian Randomization (MR) analysis. Additionally, heterogeneity was measured using Cochran's Q value, and horizontal pleiotropy was evaluated using MR-Egger 、Mendelian Randomization Pleiotropy RESidual Sum and Outlier and leave-one-out analyses.
RESULTS: The risk of brain cancer increases with the presence of atopic dermatitis, as evidenced by the odds ratios (ORs) and 95% confidence intervals (CIs),(OR = 1.0005; 95% CI = 1.0001, 1.0009; p = 0.0096). However, when conducting the analysis in reverse, no significant link was observed.
CONCLUSION: The findings from our study indicate a causative link between atopic dermatitis and brain cancer, highlighting the importance of conducting broader clinical investigations into their potential association going forward.
1479007 Oxazolo-pyrrolo-pyrazines and intermediates therefor SANDOZ Ltd 8 July 1974 [9 July 1973 31 Jan 1974] 30269/74 Heading C2C Oxazolo-pyrrolo-pyrazines of the Formula I some of which are novel, wherein R 1  is a cyano or -COX group. X being amino or C 1-6  alkoxy, and R 2  to R 5  are substituents inert to internal cyclization conditions, are obtained by cyclizing in the presence of bases pyrrolidine derivatives of the Formula II wherein R 6  is a leaving group. Compounds of the Formula II above, e.g. wherein R 6  is a p-nitrophenoxy group, may be obtained by reacting compounds of the Formula III with compounds R 6 H or R 6 SOR 6 . The compounds of the Formula III may be obtained by debenzylating the corresponding esters of Formula V R 7  being a hydrogen atom or a benzyl group. The esters of Formula V may be obtained by condensing tartronic acid derivatives or with aminoacid benzyl esters Z being chlorine, to produce acylated alanine benzyl esters of the Formula IX debenzylating these to the free acids of Formula X and condensing these with appropriate proline benzyl esters. N - (2R - 2 - Benzyloxy - 2 - carbethoxypropionyl} - L - phenyl alcinyl - L . prolinebenzyl ester, which is a compound of Formula IX above may alternatively be prepared by reacting L-phenylalanyl-L-proline-benzyl ester hydrobromide with 5-( + )-methyl benzyloxy malonic acid monoethyl ester chloride. In one example the brucine salt of the intermediate N - (2 - hydroxy - 2 - carbethoxypropionyl) - L - phenyl alanine is isolated.
After the posterior isolation of seminal vesicles, the Retzius space will be accessed and the endopelvic fascia will be incised. The bladder neck will be then incised and preserved when possible. An inter-fascial or intra-fascial nerve-sparing technique will be then performed and the posterolateral aspect of the neurovascular bundles will be preserved. The DVC will be then isolated and selectively ligated using a V-lok 3/0 barbed suture. The anterolateral fibers of the neurovascular bundles will be then identified and preserved when possible. During apical dissection, the urethral sphincter will be identified and carefully preserved. Posterior reconstruction and anastomosis will be then performed.
The aim of this study was to compare the sexual function of women with and without pregnancy-related PGP, and to investigate its relationship with physical activity (PA), kinesiophobia, and body image (BI). Demographic characteristics, sexual function (Pregnancy Sexual Response Inventory), PA (Pregnancy Physical Activity Questionnaire), kinesiophobia (Tampa Kinesiophobia Scale), and BI (Body Image in Pregnancy Scale) of 125 pregnant women were recorded. In the PGP group (n = 46), visual analogue scales were used to assess the pain intensity during resting and sexual activity, and Pelvic Girdle Questionnaire was used to evaluate the activity limitation. Although total sexual function and BI scores of the groups were similar (p > 0.05), dyspareunia during pregnancy and level of kinesiophobia were higher, and energy expenditure during moderate-intensity PA was lower in pregnant women with PGP (p < 0.05). The PGP group had moderate activity limitation and reported increased PGP intensity during sexual activities (p < 0.001). PA level was significantly correlated with sexual desire (r = 0.180), and overall sexual function was correlated with kinesiophobia (r = -0.344) and BI (r = -0.199) during pregnancy (p < 0.05). These findings suggest that pregnant women with PGP are more vulnerable to sexual dysfunctions, and there is a need to develop biopsychosocial framework-oriented management strategies which aim to improve PA level and to eliminate psychological factors such as kinesiophobia and negative BI.Clinical Trial Registration: NCT05990361.
The recommended dosage range of SIGNIFOR is 0.3 mg to 0.9 mg by subcutaneous injection twice a day. The recommended initial dose is either 0.6 mg or 0.9 mg twice a day. Titrate dose based on response and tolerability. 

Patients should be evaluated for a treatment response [clinically meaningful reduction in 24-hour urinary free cortisol (UFC) levels and/or improvement in signs or symptoms of the disease] and should continue receiving therapy with SIGNIFOR as long as benefit is derived [see Clinical Studies (14)]. Maximum UFC reduction is typically seen by two months of treatment [see Clinical Studies (14)]. For patients who are started on 0.6 mg twice a day, a dosage increase to 0.9 mg twice a day may be considered based on the response to the treatment, as long as the 0.6 mg dosage is well tolerated by the patient.

Management of suspected adverse reactions may require temporary dose reduction of SIGNIFOR. Dose reduction by 0.3 mg decrements per injection is suggested.
After admission to hospital 3 cycles of preconditioning with 5-min inflation and 5-min deflation of a blood-pressure cuff. After primary PCI/stenting 4 cycles of postconditioning (30s ischemia and 30s reperfusion).
BACKGROUND: Feline osteoarthritis (OA) leads to chronic pain and somatosensory sensitisation. In humans, sensory exposure can modulate chronic pain. Recently, electroencephalography (EEG) revealed a specific brain signature to human OA. However, EEG pain characterisation or its modulation does not exist in OA cats, and all EEG were conducted in sedated cats, using intradermal electrodes, which could alter sensory (pain) perception.
NEW METHOD: Cats (n=11) affected by OA were assessed using ten gold-plated surface electrodes. Sensory stimuli were presented in random orders: response to mechanical temporal summation, grapefruit scent and mono-chromatic wavelengths (500 nm-blue, 525 nm-green and 627 nm-red light). The recorded EEG was processed to identify event-related potentials (ERP) and to perform spectral analysis (z-score).
RESULTS: The procedure was well-tolerated. The ERPs were reported for both mechanical (F3, C3, Cz, P3, Pz) and olfactory stimuli (Cz, Pz). The main limitation was motion artifacts. Spectral analysis revealed a significant interaction between the power of EEG frequency bands and light wavelengths (p<0.001). All wavelengths considered, alpha band proportion was higher than that of delta and gamma bands (p<0.044), while the latter was lower than the beta band (p<0.016). Compared to green and red, exposure to blue light elicited distinct changes in EEG power over time (p<0.001).
COMPARISON WITH EXISTING METHOD: This is the first demonstration of EEG feasibility in conscious cats with surface electrodes recording brain activity while exposing them to sensory stimulations.
CONCLUSION: The identification of ERPs and spectral patterns opens new avenues for investigating feline chronic pain and its potential modulation through sensory interventions.
Participants assigned to this group will complete a 20-minute yogic breathing video at least 5 days per week for 4 weeks. All sessions except the initial yogic breathing session will be completed at home. Participants will complete the first session at Texas State under the supervision of the investigative team for familiarization.
PURPOSE: A pharmaceutical composition containing Cudrania tricuspidata (Carr.) Bureau ex Lavallee and Coicis semen extract is provided to suppress obesity and reduce blood glucose. CONSTITUTION: A pharmaceutical composition for suppressing obesity or reducing blood glucose contains extract of Cudrania tricuspidata (Carr.) Bureau ex Lavallee and Coicis semen in a weight ratio of 1:1. A food additive composition for suppressing obesity or reducing blood glucose contains the extract of Cudrania tricuspidata (Carr.) Bureau ex Lavallee and Coicis semen. A tablet for suppressing or reducing blood glucose contains the extract of Cudrania tricuspidata (Carr.) Bureau ex Lavallee and Coicis semen. The tablet additionally contains Radix rubra, ginseng, Discoreae Rhizoma, mulberry leaves, Hovenia dulcis fruit, stem of Hovenia dulcis Thunb, Hovenia dulcis leaf, Glycyrrhizae radix, Cinnamomi Cortex, Coptidis Rhizoma, Rubi Fructus, Cuscutae Semen, Torilidis Fructus, Lycii Fructus, Schizandrae Fructus or Astragali Radix.
A skincare mask packet includes a packing bag, a skincare mask, and a skincare liquid packaging unit. An outer edge of the packing bag has a sealing function to form a packet configuration. In addition, the skincare mask is made of materials capable of absorbing liquid. An appropriate amount of skincare liquid is further enclosed in the skincare liquid packaging unit that is accommodated in the packing bag together with the skincare mask. During usage, the packing bag is first pressed or squeezed to break the skincare liquid packaging unit, making the skincare liquid flow out the unit and absorbed by the skincare mask. After the skincare liquid has penetrated into the skincare mask, the packing bag may be sealed off for taking out the skincare mask for a skin care.
The investigators will conduct a single-blind randomised controlled trial to study the effectiveness of a yoga programme compared to a conventional adapted physical activity programme in improving balance in chronic post-stroke subjects. The primary hypothesis is that yoga is non-inferior to conventional physical activity in improving balance in chronic post-stroke patients. The secondary hypothesis is that yoga is non-inferior to conventional physical activity in improving muscle strength and functional mobility, but superior in improving anxiety, depression, social reintegration and treatment adherence.

The experiment will take place in Normandy (France), at several sites in order to maximise recruitment and minimise travel for participants. The statistical power study indicates that 42 patients per group would be required. Subjects will be randomly assigned to one of the following programmes: the YOG'AVC programme or the FAME programme. The first will involve yoga sessions with postural, respiratory, and meditative work. The second will involve more conventional exercise sessions, based on a Fitness and Mobility Exercise Program (FAME) designed for stroke survivors. Both programmes included two 60-minute group sessions per week, for 12 weeks, plus one weekly home-based session (with video or paper support). Patients will be assessed at three points in the study: before the experiment (T0), after the 12-week experiment (T1), and 3 months later (T2). The assessments will be carried out blind, using a protocol built around the International Classification of Functioning and Disability (ICF). The main criterion is balance, assessed by the Berg balance scale (0-56 point scale). The secondary outcomes will be assessed by: Timed Up and Go Test (timed task in seconds), 6-minute walk test (distance covered in meters), maximum isometric knee extension force with a manual dynamometer (newton), the activities-specific Balance Confidence Scale - Simplified (questionnaire in %), State-Trait Anxiety Inventory (2 questionnaires out of 80), Beck Depression Inventory (score out of 63), Reintegration to Normal Living Index (score out of 100). Adherence to the programme will be assessed by a logbook, between T0 and T1 by the number of group and individual sessions completed, and between T1 and T2 by the number of self-reported sessions.
Ketamine hydrochloride injection, USP for intravenous or intramuscular use, contains ketamine, a nonbarbiturate general anesthetic. Ketamine hydrochloride, USP is a white crystalline powder and has a molecular formula of C13H16ClNO•HCl and a molecular weight of 274.19. The chemical name for ketamine hydrochloride is dl-2-(o-Chlorophenyl)-2-(methylamino) cyclohexanone hydrochloride. The chemical structure of ketamine hydrochloride is:

  


  


It is formulated as a slightly acidic (pH 3.5 to 5.5) sterile solution for intravenous or intramuscular injection. Each milliliter (mL) of the multiple-dose vials contain either 10 mg ketamine base (equivalent to 11.53 mg ketamine hydrochloride), 50 mg ketamine base (equivalent to 57.67 mg ketamine hydrochloride) or 100 mg ketamine base (equivalent to 115.33 mg ketamine hydrochloride) and not more than 0.10 mg/mL benzethonium chloride added as a preservative in water for injection. The 10 mg/mL solution has been made isotonic with 6.60 mg sodium chloride.
Ischemic conditioning (IC) is a phenomenon of protecting the target organ from ischemia by directly exposing it to brief episodes of sublethal ischemia. RIC is a clinically feasible way of performing IC where episodes of ischemia and reperfusion are delivered with cyclic inflation and deflation of a blood pressure cuff on the arm or leg. Pre-clinical and preliminary clinical trials in humans show neuroprotective effects of RIC. Investigators prior work has shown that when paired with motor training, RIC enhances motor learning in healthy individuals. Based on these diversified benefits of RIC, the central hypothesis is that the multifactorial mechanisms of RIC can be harnessed as a priming agent to enhance motor learning and augment neuroplasticity in children with UCP. The Specific Aims are: 1) to determine the effects of RIC + training on bimanual skill learning and bimanual coordination, and 2) to determine the effects of RIC + training on corticospinal excitability in children with UCP. In this triple blind, randomized controlled trial, 46 children with UCP, ages 6-16 years will first undergo bimanual speed stack performance, functional upper extremity, and Transcranial Magnetic Stimulation assessments. Children will then undergo RIC/Sham conditioning plus training. Investigators will deliver RIC/sham conditioning via cyclic inflation and deflation of a pressure cuff on the paretic arm using a standard protocol. Training will involve 5 days (15 trials/day) of bimanual speed stack training for 5 days. The children will perform the same baseline assessments post-intervention. Investigators hypothesize that compared to sham conditioning + training, RIC + training will significantly enhance: 1) bimanual skill performance (decrease in movement time (sec) to complete bimanual speed stack task), 2) bimanual coordination and bimanual function (improvement in kinematic variables and increase in the Assisting Hand Assessment scores), 3) cortical excitability in the ipsilesional primary motor cortex (M1) (larger amplitude of motor evoked potentials and lower resting or active motor thresholds), and 4) reduce motor cortex inhibition (reduced short-interval intracortical inhibition and increase in intracortical facilitation in ipsilesional M1). The long-term goal is to develop effective interventions to improve function of children with UCP. Outcomes of this project will provide critical ingredients for designing Phase II trials that will determine the effects of RIC combined with different dose of intensive behavioral interventions to improve functional outcomes in children with UCP.